A Transformative Paradigm in the Treatment and Prevention of GSM
Our lead compound targets the CB2 receptors expressed in vaginal tissue. Activation of these receptors initiates a cascade of molecular signaling that mimics the effects of estrogen on vulvovaginal tissue which is restorative in nature, representing a alternative from the current treatment options. The historical safety of the natural product suggests that this synthetic derivative will share the same profile and provide women with an alternative to estrogen replacement.
Cannabis is a complex plant with over 400 active pharmaceutical ingredients of which more than 100 of them are cannabinoid compounds. The FDA recognizes the potential opportunities that cannabis or cannabis-derived compounds offer and has approved 4 cannabis-derived drugs.
Consequently, the stigma around cannabis is lifting and in exchange the market for medicinal cannabis is expected to reach $28 billion in 2024, according to Energias Market Research.
Clearly, in spite of all the scientific research that has increased awareness and demand for cannabis, it still has psychotropic effects that may not be appealing to the majority of individuals for whom it may have benefits. Therefore, Immugen is offering a non-psychoactive alternative to medicinal marijuana that could represent a paradigm shift for the treatment of GSM.
The market is untapped for a safe and efficacious treatment for this life-altering condition that can significantly impair the health, sexual function and quality of life of the woman and her partner.
Early Stage Investment Opportunity
By the Numbers
All women will experience menopause (Total Addressable Market = >1 billion women)
50% cannot be given HRT because of side effects and increased risks of cancer.
By 2025, 1.1 billion women are expected to be postmenopausal.
The space represents $600 billion of spending opportunity.
Immugen’s three pillars
Patent protection – menopause treatment
First mover advantage
Out-licensing exit strategy